Our memories make us who we are

It’s why it’s so important to protect them. Souvenaid® is nutritionally formulated to support memory function to help you continue to do all the things that make you, you.

Request a sample

How does Souvenaid® work?

Souvenaid® is a medical nutrition drink that contains a unique blend of ingredients known as Fortasyn® Connect. Souvenaid® provides the key nutritional building blocks to support the growth of brain connections. Taken daily for at least 6 months, Souvenaid supports memory function in early Alzheimers disease. Use under medical supervision.

Line drawing of a brain.
Supports memory function in early Alzheimer’s disease
Line drawing of a microscope.
Backed by 20 years of research*
Line drawing of a neuron and synapse.
Supports the growth of brain connections

Souvenaid®

Souvenaid® is a medical nutrition drink that is special formulated to support memory function in the early stages of Alzheimer’s disease.

check

Powered by Fortasyn® Connect, a unique combination of nutrients formulated to support the growth of brain connections

check

Available in 125ml ready to drink liquid or 360g powder

check

Backed by 20 years of evidence based research, supported by an extensive ongoing research program.

check

5 delicious flavours available

Souvenaid-connections-module

Join Souvenaid® Connections online exclusive program

Join our growing community of patients with early Alzheimer’s disease who believe in hope. Our goal is to provide support for every patient and carer. We hope that, with our online support and our expert team, each patient can experience the clinical outcomes available with taking Souvenaid® daily. Joining the program is FREE and includes exclusive access to the following:

  • Exclusive member pricing
  • FREE welcome pack
  • Expert support anytime, anywhere
Join now

See real life success stories

Follow the stories of people who are using Souvenaid® to help them love the lives they want.

Explore some of our informative articles

*References:
1. Scheltens P et al. Alzheimers Dement 2010; 6: 1–10.e1
2. Scheltens P et al. J Alzheimers Dis 2012; 31: 225–236
3. Soininen H et al. Alzheimer’s Dement. 2020; 1–12
4. Shah RC et al. Alzheimers Res Ther 2013; 5: 59